In a recent feature for Drug Discovery World, Diana Spencer explores how automation is reshaping drug discovery by enhancing accuracy and efficiency. As the pharmaceutical industry accelerates the search for new therapies, innovative technologies like automation and artificial intelligence (AI) are enabling researchers to process vast datasets, optimize workflows, and bring life-saving treatments to patients faster.

In the article, Sphere Bio’s Director of Science, Maryam Ahmadi, discusses the critical role of single-cell analysis in drug discovery. She highlights how Sphere Bio’s picodroplet microfluidic platforms provide high-throughput solutions for screening and isolating single cells with unparalleled precision.

“The pharmaceutical industry is in urgent need of high-throughput technologies capable of manipulating large cell numbers to identify new therapeutics and improve biotherapeutic production methods. Traditionally, these workflows require multiple pieces of equipment, are resource-intensive, time-consuming, and expensive—limiting speed-to-clinic.” – Maryam Ahmadi, Sphere Bio

Sphere Bio recently launched Cyto-Mine® Chroma, the second-generation advancement of its flagship Cyto-Mine® platform. This breakthrough technology features a four-color laser and detector system, allowing researchers to analyze multiple targets within each encapsulated cell. With enhanced multiplexing capabilities and greater assay flexibility, Cyto-Mine® Chroma is set to redefine single-cell screening and accelerate drug discovery workflows.

Discover how automation is shaping the future of drug discovery and learn more about Sphere Bio’s role in advancing single-cell analysis. Read the full article in Drug Discovery World here.